Core 3 Inhibitor Development Service

Core 3 Inhibitor Development Service

Core 3 Inhibitor Development Service at CD BioGlyco

GlcNAcβ1-3GalNAcα1-serine/threonine is the structure of O-glycan core 3, and this process is catalyzed by β1,3-N-acetylglucosaminyltransferase 6 (β3GnT6). Core 3 structures are found only in the mucins of some tissues, such as the stomach, colon, and small intestine. β3GnT6 is a key enzyme involved in a variety of biological processes and disease development, including cell signaling, blood clot formation, and tumor progression. Anti-β3GnT6 drugs or antibodies selectively interfere with or inhibit the functions of the β3GnT6 enzyme, thereby affecting its catalytic reaction and possibly affecting related biological processes. CD BioGlyco provides efficient core 3 inhibitor development service. We have generated anti-β3GnT6 antibodies that inhibit or modulate the activity of the β3GnT6 enzyme. Below are the types of services we offer.

  • Gene synthesis and cloning

CD BioGlyco provides mature β3GnT6 gene synthesis and cloning service, and we will customize the target gene sequence according to client needs.

  • Cell line establishment

CD BioGlyco establishes cell lines suitable for expressing β3GnT6, including stable transfection, screening, and amplification of highly expressing cell lines.

  • Cell culture and expansion

CD BioGlyco cultures the cells transfected with the β3GnT6 gene in an appropriate culture medium to provide the required nutrients and conditions to support cell growth and target protein expression. Through cell culture and expansion, it produces high expression levels of β3GnT6 protein.

  • Target protein expression and purification

CD BioGlyco uses expression systems (such as eukaryotic cells, bacteria, or yeast) to express β3GnT6 protein, and purifies β3GnT6 protein through a series of separation and purification methods (such as affinity chromatography, gel filtration, ion exchange chromatography, etc.).

  • Antibody preparation

CD BioGlyco injects purified β3GnT6 protein into appropriate animals (such as mice) to trigger an immune response. The antibodies produced by the animals are collected and purified through affinity chromatography and other steps to obtain anti-β3GnT6 antibodies.

Fig.1 Core 3 inhibitor development service. (CD BioGlyco)Fig.1 Core 3 inhibitor development service. (CD BioGlyco)


Technology: Flow cytometry

Journal: Proceedings of the National Academy of Sciences

IF: 12.779

Published: 2005

Results: The authors developed an anti-β3GnT6 monoclonal antibody (G8-144) to study the expression profile of β3GnT6 in gastrointestinal tissues. The G8-144 mAb recognized β3GnT6 but not any other β3GnT. In a normal colon, β3GnT6 was detectable in the Golgi region of epithelial cells (Panels B and D), but not in cancer samples (Panels E and F), thus indicating that downregulation of core 3 synthase in colon cancer had the potential to inhibit cancer cell metastasis.

Fig.2 Representative staining pattern of β3GnT6. (Iwai, et al., 2005)Fig.2 Representative staining pattern of β3GnT6. (Iwai, et al., 2005)


  • Cancer research: Overexpression of core 3 enzymes in tumor cells is associated with tumor growth, invasion, and metastasis. By developing inhibitors targeting the core 3 enzyme, the growth and spread of tumor cells may be inhibited, potentially having applications in cancer research.
  • Inflammatory disease research: Core 3 enzymes regulate the synthesis and release of inflammatory mediators. The development of core 3 inhibitors helps study the mechanisms of diseases such as rheumatoid arthritis, asthma, and inflammatory bowel disease.
  • Diabetes research: Core 3 enzymes are involved in the synthesis and decomposition of polysaccharides in the intestine and are closely related to blood sugar regulation. By developing core 3 inhibitors, blood sugar levels are modulated, potentially for use in diabetes research.


  • Specialized Inhibitor Development: CD BioGlyco utilizes the latest means and tools, such as high-throughput screening technology, to accelerate the core 3 inhibitor development process.
  • Efficient drug design: Our scientists use structure-based drug design and simulation techniques to quickly and accurately design and optimize core 3 inhibitor candidates.
  • Multi-dimensional activity assessment: CD BioGlyco verifies the action mechanism and efficacy of inhibitors through multiple activity assessment systems, including in vitro enzyme activity assays, cell experiments, and animal models.

CD BioGlyco has a professional research team and research solutions, especially in the research and development of core 3 inhibitors. We provide a custom core 3 inhibitor development service to ensure the best development strategy. Please feel free to contact us promptly if you would like to know the development process and details.


  1. Iwai, T.; et al. Core 3 synthase is down-regulated in colon carcinoma and profoundly suppresses the metastatic potential of carcinoma cells. Proceedings of the National Academy of Sciences. 2005, 102(12): 4572-4577.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.